Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

AIMS: To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation of a glucagon‐like peptide‐1 receptor agonist. MATERIALS AND METHODS: PIONEER 6 is a multinational, randomized, placebo‐controlled, double‐blind trial in patients with type 2 diabetes at high risk of CV...

Descripción completa

Detalles Bibliográficos
Autores principales: Bain, Stephen C., Mosenzon, Ofri, Arechavaleta, Rosario, Bogdański, Pawel, Comlekci, Abdurrahman, Consoli, Agostino, Deerochanawong, Chaicharn, Dungan, Kathleen, Faingold, Maria C., Farkouh, Michael E., Franco, Denise R., Gram, Jeppe, Guja, Cristian, Joshi, Pankaj, Malek, Rachid, Merino‐Torres, Juan F., Nauck, Michael A., Pedersen, Sue D., Sheu, Wayne H. ‐H., Silver, Robert J., Tack, Cees J., Tandon, Nikhil, Jeppesen, Ole K., Strange, Mette, Thomsen, Mette, Husain, Mansoor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Clinical Trial Design
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587508/
https://www.ncbi.nlm.nih.gov/pubmed/30284349
http://dx.doi.org/10.1111/dom.13553

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587508/
https://www.ncbi.nlm.nih.gov/pubmed/30284349
http://dx.doi.org/10.1111/dom.13553

Ejemplares similares